Teresa Garcia-Lezana

Teresa Garcia-Lezana

Auto-generated profile, based on publicly available information

Teresa Garcia-Lezana

Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology , Barcelona 08003

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
BLBojan Losic
Bojan Losic
ACAmanda J. Craig
Amanda J. Craig
CVCarlos Villacorta-Martin
Carlos Villacorta-Martin
SMSebastiao N. Martins-Filho
Sebastiao N. Martins-Filho
NANicholas Akers
Nicholas Akers
AVAugusto Villanueva
Augusto Villanueva
Clonal evolution of a tumor ecosystem depends on different selection pressures that are principally immune and treatment mediated. We integrate RNA-seq, DNA sequencing, TCR-seq and SNP array data across multiple regions of liver cancer specimens to map spatio-temporal interactions between cancer and immune cells. We investigate how these interactions reflect intra-tumor heterogeneity (ITH) by correlating regional neo-epitope and viral antigen burden with the regional adaptive immune response. Regional expression of passenger mutations dominantly recruits adaptive responses as opposed to hepatitis B virus and cancer-testis antigens. We detect different clonal expansion of the adaptive immune system in distant regions of the same tumor. An ITH-based gene signature improves single-biopsy patient survival predictions and an expression survey of 38,553 single cells across 7 regions of 2 patients further reveals heterogeneity in liver cancer. These data quantify transcriptomic ITH and how the different components of the HCC ecosystem interact during cancer evolution.

24 June 2021 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
ACAmanda J. Craig
Amanda J. Craig
TGTeresa Garcia-Lezana
Teresa Garcia-Lezana
MGMarina Ruiz de Galarreta
Marina Ruiz de Galarreta
CVCarlos Villacorta-Martin
Carlos Villacorta-Martin
EGEdgar Gonzalez-Kozlova
Edgar Gonzalez-Kozlova
AVAugusto Villanueva
Augusto Villanueva
Cancer testis antigens (CTAs) are an extensive gene family with a unique expression pattern restricted to germ cells, but aberrantly reactivated in cancer tissues. Studies indicate that the expression (or re-expression) of CTAs within the MAGE-A family is common in hepatocellular carcinoma (HCC). However, no systematic characterization has yet been reported. The aim of this study is to perform a comprehensive profile of CTA de-regulation in HCC and experimentally evaluate the role of MAGEA3 as a driver of HCC progression. The transcriptomic analysis of 44 multi-regionally sampled HCCs from 12 patients identified high intra-tumor heterogeneity of CTAs. In addition, a subset of CTAs was significantly overexpressed in histologically poorly differentiated regions. Further analysis of CTAs in larger patient cohorts revealed high CTA expression related to worse overall survival and several other markers of poor prognosis. Functional analysis of MAGEA3 was performed in human HCC cell lines by gene silencing and in a genetic mouse model by overexpression of MAGEA3 in the liver. Knockdown of MAGEA3 decreased cell proliferation, colony formation and increased apoptosis. MAGEA3 overexpression was associated with more aggressive tumors in vivo. In conclusion MAGEA3 enhances tumor progression and should be considered as a novel therapeutic target in HCC.

6 January 2025 in GigaScience
Verified
Journal Article
Open access
TGTeresa García-Lezana
Teresa García-Lezana
MBMaciej Bobowicz
Maciej Bobowicz
SFSantiago Frid
Santiago Frid
MRMichael W Rutherford
Michael W Rutherford
MRMikel Recuero
Mikel Recuero
JRJordi Rambla
Jordi Rambla
Background: An unprecedented amount of personal health data, with the potential to revolutionize precision medicine, is generated at health care institutions worldwide. The exploitation of such data using artificial intelligence (AI) relies on the ability to combine heterogeneous, multicentric, multimodal, and multiparametric data, as well as thoughtful representation of knowledge and data availability. Despite these possibilities, significant methodological challenges and ethicolegal constraints still impede the real-world implementation of data models. Technical details: The EuCanImage is an international consortium aimed at developing AI algorithms for precision medicine in oncology and enabling secondary use of the data based on necessary ethical approvals. The use of well-defined clinical data standards to allow interoperability was a central element within the initiative. The consortium is focused on 3 different cancer types and addresses 7 unmet clinical needs. We have conceived and implemented an innovative process to capture clinical data from hospitals, transform it into the newly developed EuCanImage data models, and then store the standardized data in permanent repositories. This new workflow combines recognized software (REDCap for data capture), data standards (FHIR for data structuring), and an existing repository (EGA for permanent data storage and sharing), with newly developed custom tools for data transformation and quality control purposes (ETL pipeline, QC scripts) to complement the gaps. Conclusion: This article synthesizes our experience and procedures for health care data interoperability, standardization, and reproducibility.

18 March 2024 in medRxiv
Verified
Preprint
Open access
PDF file
TGTeresa García-Lezana
Teresa García-Lezana
MBMaciej Bobowicz
Maciej Bobowicz
SFSantiago Frid
Santiago Frid
MRMichael W Rutherford
Michael W Rutherford
MRMikel Recuero
Mikel Recuero
JRJordi Rambla
Jordi Rambla
Background: An unprecedented amount of personal health data, with the potential to revolutionise precision medicine, is generated at healthcare institutions worldwide. The exploitation of such data using artificial intelligence relies on the ability to combine heterogeneous, multicentric, multimodal and multiparametric data, as well as thoughtful representation of knowledge and data availability. Despite these possibilities, significant methodological challenges and ethico-legal constraints still impede the real-world implementation of data models. Technical details: The EuCanImage is an international consortium aimed at developing AI algorithms for precision medicine in oncology and enabling secondary use of the data based on necessary ethical approvals. The use of well-defined clinical data standards to allow interoperability was a central element within the initiative. The consortium is focused on three different cancer types and addresses seven unmet clinical needs. We have conceived and implemented an innovative process to capture clinical data from hospitals, transform it into the newly developed EuCanImage data models and then store the standardised data in permanent repositories. This new workflow combines recognized software (REDCap for data capture), data standards (FHIR for data structuring) and an existing repository (EGA for permanent data storage and sharing), with newly developed custom tools for data transformation and quality control purposes (ETL pipeline, QC scripts) to complement the gaps. Conclusion: This article synthesises our experience and procedures for healthcare data interoperability, standardisation and reproducibility.